Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 11, 2013 - Issue 8
Submit an article Journal homepage
116
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections

Melinda M Soriano Department of Pharmacy Practice, The University of Illinois at Chicago, Chicago, IL, USA
,
Siyun Liao Department of Pharmacy Practice, The University of Illinois at Chicago, Chicago, IL, USA
&
Larry H Danziger Department of Pharmacy Practice, The University of Illinois at Chicago, Chicago, IL, USA
Pages 767-776 | Published online: 10 Jan 2014

References

  • Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: A review. Arch. Intern. Med. 161(4), 525–533 (2001).
  • Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47(9), 1162–1170 (2008).
  • McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353(23), 2433–2441 (2005).
  • Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 55(Suppl. 2), S65–S70 (2012).
  • Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173(9), 1037–1042 (2005).
  • Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control. Hosp. Epidemiol. 32(4), 387–390 (2011).
  • Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 142(7), 624–631 (2007).
  • Pawar D, Tsay R, Nelson DS et al. Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. Infect. Control Hosp. Epidemiol. 33(11), 1107–1112 (2012).
  • Weir E, Flegel K. Protecting against Clostridium difficile illness. Cmaj 172(9), 1178 (2005).
  • Cleary RK. Clostridium difficile-associated diarrhea and colitis: clinical manifestations, diagnosis, and treatment. Dis. Colon Rectum 41(11), 1435–1449 (1998).
  • Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin. Infect. Dis. 53(1), 42–48 (2011).
  • Chen FC, Woods R. Pseudomembranous panenteritis and septicaemia in a patient with ulcerative colitis. Aust. N. Z. J. Surg. 66(8), 565–567 (1996).
  • Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41(9), 1254–1260 (2005).
  • Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353(23), 2442–2449 (2005).
  • Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235(3), 363–372 (2002).
  • Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control. Hosp. Epidemiol. 26(3), 273–280 (2005).
  • McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin. Infect. Dis. 40(2), 265–272 (2005).
  • Hensgens MP, Goorhuis A, Notermans DW, van Benthem BH, Kuijper EJ. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro. Surveill. 14(45), (2009).
  • Wilcox MH, Shetty N, Fawley WN et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55(8), 1056–1063 (2012).
  • O’Donoghue C, Kyne L. Update on Clostridium difficile infection. Curr. Opin. Gastroenterol. 27(1), 38–47 (2011).
  • Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control. Hosp. Epidemiol. 31(5), 431–455 (2010).
  • Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15(12), 1067–1079 (2009).
  • McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97(7), 1769–1775 (2002).
  • Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38(6), 2386–2388 (2000).
  • Fekety R, McFarland LV, Surawicz CM et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 24(3), 324–333 (1997).
  • Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J. Hosp. Infect. 74(4), 309–318 (2010).
  • Dificid® package insert. Optimer Pharmaceuticals, Inc., San Diego, CA, USA (2013).
  • Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55(Suppl. 2), S93–103 (2012).
  • Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 54(4), 568–574 (2012).
  • Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48(12), 4898–4902 (2004).
  • Anti-Infective Drugs Advisory Committee Briefing Document Optimer Pharmaceuticals I. Dificid™ (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. (Ed. (Eds) (2011).
  • Sergio S, Pirali G, White R, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action. J. Antibiot. (Tokyo), 28(7), 543–549 (1975).
  • Osburne MS, Sonenshein AL. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J. Virol. 33(3), 945–953 (1980).
  • Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 55(Suppl. 2), S127–S131 (2012).
  • Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48(11), 4430–4434 (2004).
  • Goldstein EJ, Citron DM, Sears P et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two Phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob. Agents Chemother. 55(11), 5194–5199 (2011).
  • Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob. Agents Chemother. 55(9), 4427–4429 (2011).
  • Babakhani F, Bouillaut L, Sears P et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68(3), 515–522 (2013).
  • Babakhani F, Bouillaut L, Gomez A et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55(Suppl. 2), S162–S169 (2012).
  • Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin. Infect. Dis. 55(Suppl. 2), S132–S142 (2012).
  • Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53(1), 261–263 (2009).
  • Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin. Infect. Dis. 25(3), 729–732 (1997).
  • Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin. Infect. Dis. 55(Suppl. 2), S121–S126 (2012).
  • Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a Phase II trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 53(1), 223–228 (2009).
  • Al-Nassir WN, Sethi AK, Li Y et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob. Agents Chemother. 52(7), 2403–2406 (2008).
  • Shue YK, Sears PS, Shangle S et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52(4), 1391–1395 (2008).
  • Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364(5), 422–431 (2011).
  • Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12(4), 281–289 (2012).
  • Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55(Suppl. 2), S154–S161 (2012).
  • Mullane KM, Miller MA, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53(5), 440–447 (2011).
  • Cornely OA, Miller M, Fantin B, Mullane K, Kean Y, Gorbach S. Clostridium difficile- Associated Diarrhea in Cancer Patients Treated with Fidaxomicin or Vancomycin. Presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, 2012.
  • Mullane K, Golan Y, Crook D, Cornely O, Miller M, Louie T, Gorbach S. Renal Impairment and Responses to Fidaxomicin versus Vancomycin in Patients with Clostridium difficile Infection. Presented at: Society of Hospital Medicine Annual Meeting. San Diego, CA, 2012.
  • Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Cmaj 171(5), 466–472 (2004).
  • Miller M, Gravel D, Mulvey M et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50(2), 194–201 (2010).
  • Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J. Hosp. Infect. 82(1), 1–12 (2012).
  • Louie TJ, Miller MA, Crook DW et al. Effect of age on treatment outcomes in Clostridium difficile infection. J. Am. Geriatr. Soc. 61(2), 222–230 (2013).
  • Johnson S, Gerding DN. Fidaxomicin ‘chaser’ regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin. Infect. Dis. 56(2), 309–310 (2013).
  • Weiss K, Allgren RL, Sellers S. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clin. Infect. Dis. 55(Suppl. 2), S110–S115 (2012).
  • Sclar DA, Robison LM, Oganov AM et al. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin. Drug. Investig. 32(8), e17–e24 (2012).
  • Kuntz JL, Johnson ES, Raebel MA et al. Epidemiology and healthcare costs of incident Clostridium difficile infections identified in the outpatient healthcare setting. Infect. Control Hosp. Epidemiol. 33(10), 1031–1038 (2012).
  • McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin. Microbiol. Infect. 18(3), 282–289 (2012).
  • McFarland LV, Surawicz CM, Rubin M et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20(1), 43–50 (1999).
  • O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28(11), 1219–1227 (2007).
  • Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34(3), 346–353 (2002).
  • Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55(Suppl 2), S88–S92 (2012).
  • Greig J. Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea. Clin. Drug Investig. 33(1), 93–94 (2013).
  • Crawford T, Huesgen E, Danziger L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am. J. Health. Syst. Pharm. 69(11), 933–943 (2012).
  • Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45(3), 302–307 (2007).
  • Le F, Arora V, Shah DN et al. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy 32(2), 129–134 (2012).
  • Louie T, Gerson M, Grimard D et al. Results of a Phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). Presented at: Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007 (Abstract K-425a).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.